Skip to main content
. 2018 Oct 14;24:7340–7347. doi: 10.12659/MSM.910054

Figure 4.

Figure 4

miR-126 targets CED-9 to inhibit RCC tumorigenesis. (A) Luciferase reporter assays were performed in 293T cells after co-transfecting CED-9 wild-type or mutant UTR with miR-126. (B) The protein level of CED-9 after knocking down miR-126 in 786-O cells. (C) The protein level of CED-9 after over expression of miR-126 in 786-O cells. (D) The correlation between miR-126 andCED-9 level in RCC tumor tissues were analyzed by q-PCR. Each sample was run in triplicate and in multiple experiments for mean ±SEM. * P<0.05, ** P<0.01 compared to controls.